Not only is Maine's drug import law bad for drug innovation and patient safety, but it also makes bad economic sense as it encourages the use of more costly brand-name drugs instead of effective and cheaper generics, Paul Howard writes. Policymakers should seek ways to promote innovation and sway patients to go for health interventions with the highest value, he writes.

Full Story:

Related Summaries